TransAtlantic Petroleum Ltd. (TAT) Jumps 8.93% on February 22

Equities Staff |

TransAtlantic Petroleum Ltd. (TAT) was among the biggest gainers on the Russell 2000 for Monday February 22 as the stock popped 8.93% to $0.75, representing a gain of $0.0613 per share. Some 33,118 shares traded hands on 159 trades, compared with an average daily volume of 77,398 shares out of a total float of 41.02 million. The stock opened at $0.76 and traded with an intraday range of $0.76 to $0.72.

After today's gains, TransAtlantic Petroleum Ltd. reached a market cap of $30.66 million. TransAtlantic Petroleum Ltd. has had a trading range between $6.18 and $0.59 over the last year, and it had a 50-day SMA of $0.99 and a 200-day SMA of $2.92.

The stock has a P/E Ratio of 9.8.

TransAtlantic Petroleum Ltd is an oil and natural gas company. It is engaged in acquisition, exploration, development and production.

TransAtlantic Petroleum Ltd. is based out of Addison, TX and has some 719 employees. Its CEO is N. Mitchell.

For a complete fundamental analysis analysis of TransAtlantic Petroleum Ltd., check out Equities.com’s Stock Valuation Analysis report for TAT. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Santo Diablo Mezcal

Santo Diablo Mezcal has been created to capitalize on a boom sector of the beverage market currently full of many small unmemorable products by producing one sexy, household, easily recognizable…

Snapchat

Snapchat is the fastest way to share a moment with friends. The mobile app, allows users to not only share photos with friends but also control how long they can…